Oppenheimer: UroGen Pharma (URGN.US) rating was maintained, and the target price was adjusted from superior to superior to market, and the target price was adjusted from $34.00 to $32.00.
奥本海默：维持UroGen Pharma(URGN.US)评级，由优于大市调整至优于大市评级, 目标价由34.00美元调整至32.00美元。
Oppenheimer: UroGen Pharma (URGN.US) rating was maintained, and the target price was adjusted from superior to superior to market, and the target price was adjusted from $34.00 to $32.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.